These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9477479)

  • 21. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
    Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
    Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus.
    Martínez-Torrecuadrada JL; Langeveld JP; Venteo A; Sanz A; Dalsgaard K; Hamilton WD; Meloen RH; Casal JI
    Virology; 1999 May; 257(2):449-59. PubMed ID: 10329555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.
    van Gennip RG; van de Water SG; Maris-Veldhuis M; van Rijn PA
    PLoS One; 2012; 7(9):e44619. PubMed ID: 23049753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant bluetongue virus with hemagglutinin epitopes in VP2 has potential as a labeled vaccine.
    Guo Y; Huang L; Bi K; Xu Q; Bu Z; Wang F; Sun E
    Vet Microbiol; 2020 Sep; 248():108825. PubMed ID: 32891953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the outer capsid proteins VP2 and VP5 of bluetongue virus in Saccharomyces cerevisiae.
    Martyn JC; Gould AR; Yu M
    Virus Res; 1994 Jul; 33(1):11-25. PubMed ID: 7941697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ovine cytotoxic T lymphocyte responses to bluetongue virus.
    Janardhana V; Andrew ME; Lobato ZI; Coupar BE
    Res Vet Sci; 1999 Dec; 67(3):213-21. PubMed ID: 10607500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Comtet L; Lövgren Bengtsson K; Pringle J; Zientara S; Valarcher JF
    Clin Vaccine Immunol; 2013 Aug; 20(8):1115-22. PubMed ID: 23720365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
    Utrilla-Trigo S; Jiménez-Cabello L; Calvo-Pinilla E; Marín-López A; Lorenzo G; Sánchez-Cordón P; Moreno S; Benavides J; Gilbert S; Nogales A; Ortego J
    J Virol; 2022 Feb; 96(3):e0161421. PubMed ID: 34787454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of a conserved region of bluetongue virus protein VP2 in cross-neutralisation of bluetongue virus serotypes.
    Jyothi SJ; Patil SR; Reddy NY; Panduranga RP; Madala U; Prakash GM; Putty K
    Onderstepoort J Vet Res; 2020 Oct; 87(1):e1-e6. PubMed ID: 33054261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serological Cross-Reactions between Expressed VP2 Proteins from Different Bluetongue Virus Serotypes.
    Fay PC; Mohd Jaafar F; Batten C; Attoui H; Saunders K; Lomonossoff GP; Reid E; Horton D; Maan S; Haig D; Daly JM; Mertens PPC
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Brun A; Anguita J; Ortego J
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Double-Antigen Microsphere Immunoassay for Simultaneous Group and Serotype Detection of Bluetongue Virus Antibodies.
    Breard E; Garnier A; Despres P; Blaise Boisseau S; Comtet L; Viarouge C; Bakkali-Kassimi L; Pourquier P; Hudelet P; Vitour D; Rossi S; Belbis G; Sailleau C; Zientara S
    Transbound Emerg Dis; 2017 Dec; 64(6):1837-1847. PubMed ID: 27667484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potency and efficacy of inactivated bluetongue virus vaccines.
    Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
    Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous expression of Bluetongue VP2 viral protein fragment in Pichia pastoris.
    Athmaram TN; Bali G; Kahng GG; Dwarakanath S
    Virus Genes; 2007 Oct; 35(2):265-71. PubMed ID: 17253126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.
    Anderson J; Bréard E; Lövgren Bengtsson K; Grönvik KO; Zientara S; Valarcher JF; Hägglund S
    Clin Vaccine Immunol; 2014 Mar; 21(3):443-52. PubMed ID: 24451327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice.
    Legisa DM; Perez Aguirreburualde MS; Gonzalez FN; Marin-Lopez A; Ruiz V; Wigdorovitz A; Martinez-Escribano JA; Ortego J; Dus Santos MJ
    Vaccine; 2015 May; 33(22):2614-9. PubMed ID: 25858859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
    Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
    Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.